PET/MRI FDOPA – Brain

What is PET/MRI FDOPA – Brain?

PET/MRI FDOPA – Brain is a specialized brain imaging examination that combines 18F-FDOPA PET with detailed MRI of the brain in a single diagnostic study.

The PET component provides information about the biological and metabolic activity of brain tissue, while MRI provides highly detailed images of the brain's anatomy and structure.

Combining these two types of imaging can help doctors determine not only where an abnormal area is located, but also whether that tissue shows increased biological activity.

This can be particularly valuable in patients with known or suspected brain tumors when conventional MRI alone does not provide all the information needed for diagnosis or treatment planning.

What is 18F-FDOPA?

18F-FDOPA, also called fluorodopa or F-DOPA, is a radioactive tracer used during PET imaging.

It is related to the amino acid levodopa and is transported into certain tissues through amino-acid transport pathways.

Many brain tumors, particularly some gliomas, can demonstrate increased amino-acid transport. This may result in increased FDOPA uptake within metabolically active tumor tissue.

The tracer therefore provides information that complements the structural information obtained from MRI.

Why is FDOPA useful for brain imaging?

Normal brain tissue can show relatively high glucose metabolism, which can sometimes limit the contrast of conventional FDG PET imaging in the brain.

Amino-acid PET tracers such as FDOPA use different biological pathways and may provide improved tumor-to-background contrast in selected brain tumors.

This makes FDOPA particularly useful in certain neuro-oncology applications.

Why combine FDOPA PET with MRI?

PET and MRI provide complementary information.

MRI provides detailed information about:

• Tumor location
• Tumor size
• Brain anatomy
• Contrast enhancement
• Swelling or edema
• Mass effect
• Relationship to surrounding brain structures
• Post-surgical changes
• Changes after radiotherapy or other treatments

FDOPA PET can provide information about:

• Amino-acid transport
• Metabolic tumor activity
• Biologically active tumor tissue
• Areas of increased tracer uptake
• Potential active disease beyond structural abnormalities seen on MRI

When both datasets are evaluated together, doctors can obtain a more complete picture of the disease.

What is PET/MRI FDOPA – Brain used for?

PET/MRI FDOPA may be used in selected patients for:

• Evaluation of primary brain tumors
• Assessment of gliomas
• Evaluation of suspected glioma recurrence
• Assessment of residual active tumor
• Differentiation between recurrent tumor and treatment-related changes
• Evaluation of tumor extent
• Identification of metabolically active tumor regions
• Clarification of uncertain MRI findings
• Biopsy planning
• Neurosurgical planning
• Radiotherapy planning
• Assessment of treatment response
• Follow-up after brain tumor treatment

The decision to perform FDOPA PET/MRI depends on the patient's diagnosis, previous treatment, MRI findings and the specific clinical question.

PET/MRI FDOPA for gliomas

Gliomas are among the most important applications of amino-acid PET imaging.

FDOPA PET/MRI may provide additional information in selected patients with:

• Low-grade glioma
• High-grade glioma
• Astrocytoma
• Oligodendroglioma
• Glioblastoma
• Recurrent glioma
• Previously treated brain tumors

Gliomas may contain areas with different levels of biological activity.

FDOPA PET can help identify regions showing greater tracer uptake, while MRI demonstrates their precise anatomical location.

PET/MRI FDOPA for glioblastoma

Glioblastoma is an aggressive type of primary brain tumor that frequently requires repeated imaging during and after treatment.

In selected patients, FDOPA PET/MRI may help:

• Assess metabolically active disease
• Evaluate suspicious changes on follow-up MRI
• Investigate suspected recurrence
• Determine the extent of active tumor
• Support biopsy targeting
• Assist with treatment planning
• Evaluate changes following therapy

PET/MRI findings must always be interpreted together with pathology, previous imaging, molecular tumor characteristics and treatment history.

Can FDOPA PET/MRI detect recurrent brain tumors?

FDOPA PET/MRI may be particularly useful when doctors suspect that a brain tumor has returned after treatment.

After surgery, chemotherapy or radiotherapy, MRI may show new or increasing abnormalities.

These findings can represent:

• Recurrent tumor
• Treatment effect
• Radiation-related changes
• Inflammation
• Tissue injury
• Radiation necrosis
• Post-surgical changes

Because FDOPA PET provides metabolic information, it may help determine whether suspicious tissue is biologically active.

Can FDOPA PET/MRI distinguish tumor recurrence from radiation necrosis?

Distinguishing recurrent tumor from radiation necrosis can be challenging with conventional MRI.

Radiation treatment can produce tissue changes that sometimes resemble recurrent tumor.

FDOPA PET may provide additional information by assessing amino-acid tracer uptake within the suspicious area.

Higher or abnormal uptake patterns may support the presence of active tumor, while lower uptake may favor treatment-related changes in some situations.

However, no imaging test is perfect.

The final interpretation may also require:

• Follow-up imaging
• Advanced MRI techniques
• Clinical assessment
• Comparison with previous scans
• Multidisciplinary review
• Biopsy in selected cases

PET/MRI FDOPA for biopsy planning

Brain tumors may be heterogeneous, meaning that different regions of the same tumor can have different biological characteristics.

FDOPA PET may help identify areas with greater metabolic activity.

This information can assist the medical team in selecting a potentially more representative biopsy target.

Accurate biopsy targeting can be particularly important when a tumor contains both lower-activity and higher-activity regions.

PET/MRI FDOPA for surgical planning

Before brain tumor surgery, understanding the exact location and extent of disease is important.

MRI provides detailed anatomical information, while FDOPA PET may highlight metabolically active tumor tissue.

Together, they may help the neurosurgical team evaluate:

• Tumor location
• Tumor boundaries
• Relationship to surrounding brain structures
• Areas of increased biological activity
• Suspicious regions beyond conventional MRI abnormalities

The final surgical plan depends on the complete neurological, radiological and pathological assessment.

PET/MRI FDOPA for radiotherapy planning

FDOPA PET may also provide complementary information during radiotherapy planning.

Areas of increased metabolic activity can be correlated with MRI findings and other treatment-planning images.

In selected cases, this may help the radiation oncology team better define biologically active tumor regions.

PET findings do not replace standard radiotherapy planning methods but may provide additional information when clinically appropriate.

PET/MRI FDOPA for treatment response

PET/MRI FDOPA may be used during follow-up to evaluate how a brain tumor is responding to treatment.

Doctors may assess:

• Changes in FDOPA uptake
• Changes in tumor size
• Changes in MRI appearance
• Development of new active areas
• Reduction in metabolically active tumor
• Suspicion of progression

Comparing the current examination with previous PET and MRI studies can be particularly useful.

FDOPA PET and neurological disorders

FDOPA PET is not used only in oncology.

Because FDOPA is related to dopamine metabolism, specialized FDOPA PET examinations may also be used to evaluate the presynaptic dopaminergic system in selected neurological disorders.

Potential applications can include certain movement disorders and parkinsonian syndromes.

However, neurological FDOPA PET protocols are different from brain tumor imaging protocols.

The clinical indication should therefore be clearly defined before the examination.

How is PET/MRI FDOPA – Brain performed?

The exact procedure can vary between imaging centers.

The examination usually includes:

• Medical history review
• Review of previous imaging
• MRI safety screening
• Intravenous cannula placement
• Injection of 18F-FDOPA
• A specific uptake period
• PET imaging of the brain
• MRI brain sequences
• Combined interpretation of PET and MRI images

The PET and MRI components may be performed on an integrated PET/MRI scanner.

How should I prepare for PET/MRI FDOPA – Brain?

Preparation instructions vary according to the imaging protocol.

Patients may be asked to:

• Fast for several hours before the scan
• Drink plain water
• Avoid food and calorie-containing drinks during the fasting period
• Follow specific medication instructions
• Bring previous MRI, PET or CT images
• Bring pathology reports and previous treatment information
• Arrive at the scheduled time

Because radioactive tracers are prepared for specific appointments, arriving on time is particularly important.

Should I stop my medications before FDOPA PET?

Patients should not stop any medication unless specifically instructed by the imaging team.

This is especially important for neurological medications.

If the examination is being performed for a neurological indication, the center may provide specific instructions regarding medications such as levodopa or carbidopa.

Always follow the preparation protocol provided by the nuclear medicine department.

What should I tell the imaging center before PET/MRI?

Tell the medical team if you:

• Are pregnant or may be pregnant
• Are breastfeeding
• Have kidney disease
• Have severe claustrophobia
• Have difficulty remaining still
• Have a pacemaker
• Have an implanted defibrillator
• Have a cochlear implant
• Have a neurostimulator
• Have an implanted medication pump
• Have aneurysm clips
• Have metallic fragments in the body
• Have shrapnel or previous metal injuries
• Have had previous surgery involving implants
• Have previously reacted to MRI contrast

MRI safety screening is essential before the examination.

Is MRI contrast used?

Some PET/MRI FDOPA brain protocols include intravenous gadolinium-based MRI contrast, while others may not require it.

Contrast can provide additional information about:

• Tumor enhancement
• Blood-brain barrier disruption
• Tumor anatomy
• Treatment-related changes

Patients should inform the medical team if they have:

• Severe kidney disease
• Kidney failure
• Previous gadolinium reaction
• Pregnancy or possible pregnancy

How long does PET/MRI FDOPA – Brain take?

The total appointment may take approximately 1.5 to 3 hours, although the exact duration varies according to the protocol.

The appointment can include:

• Registration and preparation
• Medical assessment
• Tracer administration
• Uptake time
• PET acquisition
• MRI sequences
• Additional imaging when required

The imaging center will provide the exact expected duration.

Is the scan painful?

PET/MRI FDOPA is generally not painful.

The main invasive part of the examination is placement of an intravenous cannula for administration of the radiotracer and, when required, MRI contrast.

Some patients may experience discomfort because of:

• Remaining still for an extended period
• Lying inside the MRI scanner
• Loud MRI sounds
• Claustrophobia

Hearing protection is normally provided.

Does PET/MRI FDOPA use radiation?

Yes.

The PET component uses a small amount of radioactive material containing fluorine-18.

The MRI component itself does not use ionizing radiation.

The radioactive tracer gradually loses its radioactivity and is eliminated from the body.

Is FDOPA PET/MRI safe?

PET/MRI FDOPA is generally considered safe when performed for an appropriate clinical indication.

Important safety considerations include:

• Small radiation exposure from the PET radiotracer
• MRI safety screening
• Implanted devices or metal
• Pregnancy
• Breastfeeding
• Kidney function if MRI contrast is required
• Previous contrast reactions

The imaging team evaluates these factors before the examination.

PET/MRI FDOPA and pregnancy

Patients who are pregnant or may be pregnant must inform the nuclear medicine department before receiving the radiotracer.

Because PET involves radioactive material, the medical team will assess whether the examination should:

• Proceed because of clinical necessity
• Be postponed
• Be modified
• Be replaced with another imaging test

PET/MRI FDOPA and breastfeeding

Breastfeeding patients should inform the nuclear medicine team before the examination.

Specific instructions may be required after administration of 18F-FDOPA.

The duration of any breastfeeding interruption should be based on the radiopharmaceutical and the local nuclear medicine protocol.

What happens after the examination?

Most patients can leave the imaging center after the scan unless sedation has been used.

Patients may be advised to:

• Drink fluids
• Urinate regularly
• Follow any radiation-safety instructions
• Resume normal activities unless advised otherwise
• Follow breastfeeding instructions when applicable

Who interprets PET/MRI FDOPA?

FDOPA PET/MRI requires specialized interpretation.

The examination may be reviewed by specialists in:

• Nuclear medicine
• Neuroradiology
• Diagnostic radiology
• Neuro-oncology imaging

The imaging findings are interpreted together with:

• Previous MRI examinations
• Previous PET examinations
• Pathology results
• Tumor molecular profile
• Previous surgery
• Radiotherapy
• Chemotherapy
• Current symptoms
• Clinical examination

What does a PET/MRI FDOPA report include?

The report may describe:

• Areas of abnormal FDOPA uptake
• Intensity and pattern of tracer uptake
• Location of suspicious tissue
• Tumor size
• MRI characteristics
• Extent of abnormality
• Relationship to surrounding structures
• Findings suggesting active tumor
• Findings suggesting treatment-related changes
• Comparison with previous examinations
• Treatment response
• Suspicion of progression or recurrence

Does increased FDOPA uptake always mean brain cancer?

No.

Increased FDOPA uptake must be interpreted carefully.

Although increased uptake may occur in active tumor tissue, PET findings alone cannot confirm cancer.

Doctors evaluate the PET findings together with:

• MRI appearance
• Location of uptake
• Pattern of uptake
• Pathology
• Previous treatment
• Clinical history

Can a normal FDOPA PET/MRI completely exclude a brain tumor?

No.

Some tumors may demonstrate relatively low FDOPA uptake.

For this reason, a normal or low-uptake PET result does not automatically exclude the presence of a brain tumor.

MRI, clinical findings and other diagnostic information remain important.

What are the benefits of PET/MRI FDOPA – Brain?

Potential benefits include:

• Molecular and anatomical brain imaging in one examination
• Detailed visualization of brain structures
• Identification of metabolically active tumor tissue
• Additional information when MRI findings are unclear
• Evaluation of suspected recurrence
• Assistance in differentiating active tumor from treatment-related changes
• Support for biopsy targeting
• Support for surgical planning
• Support for radiotherapy planning
• Treatment-response assessment
• Excellent soft-tissue imaging from MRI
• Lower radiation exposure than comparable PET/CT protocols in many situations because MRI does not use X-rays

What are the limitations of PET/MRI FDOPA – Brain?

Limitations may include:

• Limited availability
• Higher cost in some healthcare systems
• Longer examination time
• Need for specialized PET and neuroradiology expertise
• Claustrophobia
• MRI restrictions with some implanted devices
• FDOPA uptake is not specific for cancer in every situation
• Some tumors may show low tracer uptake
• Results may not eliminate the need for biopsy
• Clinical usefulness varies according to tumor type and indication

Diagnosis and Treatment

PET/MRI FDOPA is a diagnostic examination and does not directly treat brain tumors.

Its findings can contribute to several important treatment decisions.

Tumor characterization

The combination of FDOPA PET and MRI can provide information about both tumor structure and biological activity.

Determining tumor extent

PET/MRI may help identify metabolically active areas and determine their relationship to MRI abnormalities and surrounding brain structures.

Evaluating suspected recurrence

In patients previously treated for brain tumors, FDOPA PET/MRI may provide additional information when MRI findings are uncertain.

Guiding biopsy

Areas with increased FDOPA uptake may help identify metabolically active targets for biopsy in selected tumors.

Supporting neurosurgical planning

Combined metabolic and anatomical information can help the neurosurgical team understand tumor distribution and identify regions of concern before surgery.

Supporting radiotherapy planning

FDOPA PET findings may be incorporated with MRI and other imaging information to help characterize active disease during radiotherapy planning in selected cases.

Evaluating treatment response

Changes in tracer uptake and MRI appearance during follow-up may help determine whether disease is responding to treatment, remaining stable or progressing.

Treatment decisions should always be based on the complete clinical picture, including pathology, molecular tumor testing, imaging findings, neurological assessment and multidisciplinary specialist review.

Frequently Asked Questions

What is an FDOPA PET/MRI brain scan?

It is a specialized brain imaging examination that combines PET using the radioactive tracer 18F-FDOPA with high-resolution MRI.

Why is FDOPA used for brain tumors?

FDOPA uses amino-acid transport pathways that can be increased in some brain tumors, allowing metabolically active tumor tissue to become visible on PET imaging.

Is FDOPA PET/MRI better than MRI alone?

Neither test universally replaces the other. MRI provides detailed structural information, while FDOPA PET provides metabolic information. Combining them can be helpful when additional biological information is needed.

Is FDOPA PET/MRI used for gliomas?

Yes. Gliomas are one of the important clinical applications of amino-acid PET imaging.

Is FDOPA PET/MRI used for glioblastoma?

It may be used in selected patients with glioblastoma to evaluate active tumor, suspected recurrence, treatment response or to support treatment planning.

Can FDOPA PET/MRI detect recurrence after brain tumor treatment?

It may help assess suspected recurrent tumor, particularly when MRI findings are difficult to distinguish from treatment-related changes.

Can FDOPA PET differentiate radiation necrosis from recurrent tumor?

FDOPA PET may provide useful additional information in this situation, but no imaging test is completely definitive. Additional imaging, follow-up or biopsy may sometimes be required.

Can FDOPA PET/MRI help plan a brain biopsy?

Yes, in selected cases it may help identify metabolically active regions that can be considered when selecting a biopsy target.

Do I need to fast before FDOPA PET/MRI?

Many protocols require fasting for several hours. The exact preparation depends on the imaging center and clinical indication.

Can I drink water before the scan?

Plain water is generally permitted unless the imaging team provides different instructions.

Should I stop my medications?

Do not stop medications unless specifically instructed by the medical team.

Will I need MRI contrast?

Not always. Gadolinium contrast may be administered when additional MRI information is required.

How long does the examination take?

The total appointment commonly lasts approximately 1.5 to 3 hours, depending on the imaging protocol.

Does FDOPA PET/MRI expose me to radiation?

The PET component uses a small amount of radioactive tracer. MRI itself does not use ionizing radiation.

When will I receive the results?

Reporting times vary between centers. Because the examination combines PET and detailed brain MRI, the images may require specialized review and comparison with previous studies.